Assertio (ASRT)
(Delayed Data from NSDQ)
$1.17 USD
-0.04 (-3.31%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $1.18 +0.01 (0.85%) 7:40 PM ET
4-Sell of 5 4
C Value C Growth C Momentum C VGM
Price, Consensus and EPS Surprise
ASRT 1.17 -0.04(-3.31%)
Will ASRT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ASRT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ASRT
Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ASRT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
Other News for ASRT
Assertio Therapeutics: Strong Buy Rating on Robust Portfolio and Strategic Growth
Assertio Holdings management to meet virtually with Lake Street
Assertio Holdings management to meet virtually with Lake Street
Assertio Therapeutics: A Strong Buy on Robust Financial Performance and Strategic Growth Potential
Buy Rating Affirmed for Assertio Therapeutics on Strong Financials and Market Position